In non-melanoma cancers, such as breast, colorectal, and renal cancers or glioblastoma, EVs have been shown to transfer different variants of VEGF with a much lower affinity for antiangiogenic drugs (mainly bevacizumab) than soluble VEGF in plasma. Here, VEGFA is linked to renal carcinoma.